Table 1.
Vaccine | Age | Dose | Vaccination schedule/route of administration | Booster dose |
---|---|---|---|---|
Hepatitis B (Engerix B) | ≥20 years | 40 mcg | 0, 1, 2, and 6 months/IM | Yes, when anti-HBsAb <10 IU/L |
<20 years | 10 mcg | 0, 1, and 6 months/IM | Yes, when anti-HBsAb <10 IU/L | |
Influenza | 3–8 years | 15 mcg | Annually/IM | No |
9–12 years | 15 mcg | Annually/IM | No | |
>12 years | 15 mcg | Annually/IM | No | |
Pneumococcal | No | |||
Vaccine naive | 6–18 years | 1 dose of PCV13 stat | ||
Completed PCV | 6–18 years | - | Administer 1 dose of PPSV23 at age ≥2 years and ≥8 weeks after last indicated dose of PCV13 | Administer 1 dose of PPSV23 after 5 years |
Vaccine naive | 19–64 years | 1 dose of PCV13 stat | Administer 1 dose of PPSV23 ≥8 weeks later | Administer 1 dose of PPSV23 at ≥5 years |
Prior vaccination | ≥65 years | 1 dose of PCV13 stat | Administer 1 dose of PPSV23 ≥8 weeks later but must be ≥5 years after the last dose of PPSV23 | No |
HBsAg, Hepatitis B surface antigen; IM, intramuscular; PCV, pneumococcal vaccine; PPSV, pneumococcal polysaccharide vaccine.